Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849745 · ClinicalTrials.gov registry record · Phase 1
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00849745 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 4 participants.
The verdict
NCT00849745, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Autoimmune diseases present a special challenge to clinicians and the aim of this protocol is to serve as a last-line effort for patients with unmanageable disease. The primary purpose of this study is to assess feasibility in terms of toxicity and engraftment of a less toxic, nonablative conditioning regimen of Campath-1H, moderate dose fludarabine, and cyclophosphamide for patients with severe autoimmune diseases.
Interventions
- PROCEDURE Nonmyeloablative allogeneic stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2003-01 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849745
The ClinicalTrials.gov registry entry for NCT00849745 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nonmyeloablative allogeneic stem cell transplant is the first listed.
NCT00849745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00849745 about?
NCT00849745 is a clinical study titled "Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases". Autoimmune diseases present a special challenge to clinicians and the aim of this protocol is to serve as a last-line effort for patients with unmanageable disease. The primary purpose of this study is to assess feasibility in terms of toxicity and engraftment of a less toxic, nonablative conditioni...
What is the current status of trial NCT00849745?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2003-01. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00849745?
The interventions under investigation include: Nonmyeloablative allogeneic stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00849745?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.